Articles tagged with: Patients

VOICE 2018: From bedside to bench

Posted in General News, Engagement Published by Bethan Warman 12 September 2018

VOICE 2018: From bedside to bench

Last week, BCI held the 2018 VOICE (Vision On Information, Confidence & Engagement) course- a study week that aims to take patient advocates from bedside to bench by providing an introduction to basic cancer biology, research terminology and study design. This unique course was developed by Independent Cancer Patients’ Voice (ICPV)- a patient advocate group led by patients for patients- to empower patient advocates and increase their confidence to get involved in the cancer conversation.

Pancreatic Cancer UK Grand Challenge

Posted in General News, Grants & Awards Published by Bethan Warman 27 July 2018

PCUK’s largest ever research fund

Pancreatic Cancer UK Grand Challenge

Our Director, Prof Nicholas Lemoine, and a team of researchers from the BCI and King’s College London have been awarded the Pancreatic Cancer UK (PCUK) Grand Challenge- PCUK’s largest ever research fund. The grant will be used for the development of a type of immunotherapy, known as CAR-T cell therapy, to treat pancreatic cancer.

Immunotherapy harnesses the body’s own immune system to identify and kill cancer cells, and has been demonstrated to be an effective treatment option in a variety of cancer types. In CAR-T cell therapy, T cells- key immune cells responsible for fighting infected cells- are isolated from patient blood samples, modified outside of the body and reinjected back into the patient. Once back in the body, the T cells are equipped to target and attack tumours.

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Posted in General News, Conferences, BCI on the Road Published by Bethan Warman 15 June 2018

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. The Centre Lead of our Centre for Experimental Cancer Medicine (CECM), Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles of the CECM and Director of the Barts Cancer Centre, presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.

Research suggests improved detection rates are needed to maximise cancer prevention

Posted in General News, Publications Published by Bethan Warman 08 June 2018

Research suggests improved detection rates are needed to maximise cancer prevention

Current detection strategies are found to have identified only 2.6% of the BRCA gene mutation carriers in the Greater London population, according to a recent study published in the Journal of Medical genetics. The findings of the study, performed by researchers from the BCI’s Centre for Experimental Cancer Medicine, led by Dr Ranjit Manchanda, suggest that enhanced and new approaches are required to maximise the opportunity for breast and ovarian cancer prevention.

BRCA1 and BRCA2 mutations are associated with an increased risk of breast and ovarian cancer. A recent study has shown that about 72 and 69% of women who inherit a harmful mutation in the BRCA1 and BRCA2 genes, respectively, develop breast cancer by 80 years of age. Additionally, 44 and 17% of women who inherit a harmful mutation in the BRCA1 and BRCA2 genes, respectively, develop ovarian cancer by 80 years of age. Identifying mutation carriers is therefore critical to reduce the number of BRCA-associated cancers.

International Clinical Trials Day 2018

Posted in General News Published by Bethan Warman 21 May 2018

International Clinical Trials Day 2018

International Clinical Trials Day is celebrated on 20th May each year in recognition of the clinical trials conducted around the world, which ensure that research from the laboratory can be translated into patient benefit. The progress that is continuing to be made in cancer research, resulting in cancer survival rates doubling in the last 40 years, would not be possible without the researchers, clinicians, nurses and, of course, patients that are involved in clinical trials each year.

Fellows inaugurated at new Rutherford Academy of Population Genomics and Health Data Science

Posted in General News, Grants & Awards Published by Bethan Warman 16 May 2018

Fellows inaugurated at new Rutherford Academy of Population Genomics and Health Data Science

Queen Mary University of London has appointed four research fellows to its new Rutherford Academy of Population Genomics and Health Data Science, funded by the Medical Research Council and UK Research and Innovation’s Rutherford Fund. Two of the fellows include BCI’s Dr Kit Curtius and Dr Dayem Ullah.

Queen Mary’s new Rutherford Academy will be aligned to its research as a partner of the London substantive site of Health Data Research UK - a major new initiative to transform health through data science. Forty two of these prestigious fellowships were awarded following a rigorous national competition, resulting in four fellowships at Queen Mary out of a total of fourteen awarded to London universities.

London Pancreas Workshop 2018

Posted in General News, BCI Spotlight Articles, Events Published by Bethan Warman 11 May 2018

A forum for state-of-the-art clinical and basic research in pancreatic cancer

London Pancreas Workshop 2018

On Friday 4th May, BCI hosted the seventh London Pancreas Workshop, co-organised by Prof Hemant Kocher and our Director Prof Nick Lemoine, which attracted delegates from across Europe and America, with over 140 attendees in total. The biennial event is recognised as a forum for state-of-the-art clinical and basic research in pancreatic cancer.

The areas of focus for this year’s workshop were diagnostics, clinical trials and preclinical work for targeting pancreatic cancer. We heard a variety of interesting talks in these areas, delivered by researchers renowned in their fields.

BCI and KCL collaboration develops a clinically-relevant CAR-T cell imaging system

Posted in General News, Publications Published by Bethan Warman 19 April 2018

BCI and KCL collaboration develops a clinically-relevant CAR-T cell imaging system

A collaboration involving researchers from BCI’s Centre for Molecular Oncology, led by Dr Jane Sosabowski, and the ImmunoEngineering Group of King’s College London (KCL), led by Dr Sophie Papa, has developed an effective and clinically-relevant imaging system to monitor chimeric antigen receptor (CAR)-T cells within the body. This system reduced the tumour burden in a pre-clinical model of prostate cancer and allowed for repeated and non-invasive assessment of CAR-T cell localisation.

Determining the mechanisms of response and resistance to treatment in bladder cancer

Posted in General News, Publications Published by Bethan Warman 29 March 2018

Improving the efficacy of immune checkpoint inhibitors

Determining the mechanisms of response and resistance to treatment in bladder cancer

A worldwide collaboration involving BCI’s Prof Thomas Powles, Centre for Experimental Cancer Medicine, has revealed mechanisms involved in the development of response and resistance to an immune checkpoint inhibitor in metastatic urothelial cancer. The findings may highlight ways to improve the efficacy of this treatment in the hope of achieving long-term remission for patients.

Immune checkpoint inhibitors, a class of immunotherapeutic drug, have been shown to induce robust responses in patients with a variety of cancer types. These drugs block proteins that prevent the immune system from destroying cancer cells.

Some leukaemia patients may be missing out on new treatments

Posted in General News, Publications Published by Bethan Warman 11 January 2018

Some leukaemia patients may be missing out on new treatments

Patients with an aggressive form of leukaemia, currently ineligible for any type of targeted therapy, may in fact benefit from new drugs, according to new research by Barts Cancer Institute at Queen Mary University of London.

One such drug, named midostaurin, was recently approved by the US Food and Drug Administration to treat this type of leukaemia, but only patients who show mutations on a gene named FLT3 are eligible for treatment.

[12  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.